Table 2 Prevalence of HUA and UA levels in 2009 and 2019 participants in each age category

UA level

2009 participants

245 ± 51.3

(4.12 ± 0.86)

343 ± 61.5

(5.77 ± 1.03) ^△

235 ± 47.0

(3.95 ± 0.79)

347 ± 66.1

(5.83 ± 1.11) ^△

240 ± 48.6

(4.03 ± 0.82)

356 ± 72.0

(5.98 ± 1.21) ^△

261 ± 55.4

(4.39 ± 0.93)

349 ± 71.7

(5.87 ± 1.21) ^△

281 ± 61.6

(4.72 ± 1.03)

345 ± 73.1

(5.80 ± 1.23)^△

289 ± 67.8

(4.86 ± 1.14)

346 ± 74.9

(5.82 ± 1.26) ^△

250 ± 55.2

(4.20 ± 0.93)

349 ± 70.0

(5.87 ± 1.18) ^*△

[μmol/L (mg/dl)]

2019 participants

270 ± 49.7

(4.54 ± 0.84) ^**

389 ± 79.6

(6.54 ± 1.34) ^**△

263 ± 52.5

(4.42 ± 0.88) ^**

387 ± 73.6

(6.51 ± 1.24) ^**△

253 ± 50.5

(4.25 ± 0.85) ^**

373 ± 73.1

(6.27 ± 1.23)^**△

274 ± 52.6

(4.61 ± 0.89) ^**

362 ± 75.0

(6.09 ± 1.26)^**△

284 ± 57.0

(4.77 ± 0.96)

359 ± 75.5

(6.04 ± 1.27)^**△

291 ± 58.5

(4.89 ± 0.98)

363 ± 84.0

(6.10 ± 1.41) ^**△

267 ± 53.2

(4.49 ± 0.89)^**

373 ± 76.2

(6.27 ± 1.28)^**△

Prevalence of HUA, %

(95% CI)

2009 participants

2.0

(0.3–3.8)

10.0

(6.3–13.8)^△

1.2

(0.1–2.2)

14.2

(11.7–16.7)^△

1.3

(0.3–2.3)

16.9

(14.5–19.3)^△

6.0

(2.9–9.0)

15.8

(12.7–18.9)^△

10.7

(6.3–15.0)

14.3

(10.7–17.9)

13.8

(6.7–20.9)

14.1

(10.2–17.9)

3.8

(2.9–4.7)

15.0

(13.7–16.2)^△

2019 participants

5.2

(3.5–6.9) ^**

31.9

(28.9–34.9)^**△

5.5

(4.1–6.9) ^**

29.9

(27.9–32.0)^△

2.8

(1.8–3.9)

23.4

(21.6–25.3)^**△

6.5

(4.8–8.3)

20.7

(18.9–22.5)^*△

9.4

(6.3–12.5)

19.5

(17.0–22.0)^**△

12.5

(6.7–18.3)

24.7

(20.6–28.7)^**△

5.6

(4.8–6.3) ^**

24.8

(23.9–25.7)^**△